OpenCRISPR-1 is a gene editing tool designed de novo using artificial intelligence technology, with a Cas9-like protein as its core component. This protein has undergone extensive sequence re-engineering, featuring up to 400 mutations compared to the widely used SpCas9, and nearly 200 distinct differences from any known natural CRISPR-associated protein. Despite these extensive modifications, the product retains gene editing efficiency and target specificity comparable to, or even superior than, SpCas9.

Features

Protein purity: ≥95%;

Bacterial endotoxin: <10 EU/mg;

Escherichia coli host cell DNA: <3 ng/mL;

Escherichia coli host cell protein: <0.1 ppm;

Mycoplasma contamination test: negative.

No residual nuclease, nicking enzyme, RNAase, or phosphatase (<0.0001 U);

Specifications

Components

Storage

This product should be stored at -25~-15℃ for 1 year.

Application

Genome editing based on CRISPR/Cas technology;

Genetic modification of cell and gene therapy products (e.g., hematopoietic stem cells, T cells);

In vitro screening of effective sgRNAs;

In vitro cleavage of target DNA.

Figures

1.In vitro cleavage assay: In vitro cleavage activity comparable to Cas9

We compared the in vitro cleavage activity of Yeasen's OpenCRISPR-1 and Cas9 by targeting the same sequence using identical sgRNAs. The results demonstrate that the in vitro cleavage activity of OpenCRISPR-1 is comparable to that of Cas9.

Figure 1. Comparison of in vitro cleavage activity between OpenCRISPR-1 and Cas9.

2.Customer case: OpenCRISPR-1 shows gene editing efficiency comparable to Cas9

We conducted gene editing experiments on CD4 and CD8 cells using Yeasen's OpenCRISPR-1 and Cas9 with identical sgRNAs. The results indicate that the editing efficiency of OpenCRISPR-1 is comparable to that of Cas9.

Figure 2. Comparison of gene editing efficiency between OpenCRISPR-1 and Cas9.

Documents:

Safety Data Sheet

14703_MSDS_HB250923_EN.PDF

Manuals

14703_Manual_Ver.EN20250923.pdf